EE200100293A - Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II - Google Patents

Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II

Info

Publication number
EE200100293A
EE200100293A EEP200100293A EEP200100293A EE200100293A EE 200100293 A EE200100293 A EE 200100293A EE P200100293 A EEP200100293 A EE P200100293A EE P200100293 A EEP200100293 A EE P200100293A EE 200100293 A EE200100293 A EE 200100293A
Authority
EE
Estonia
Prior art keywords
dosage form
controlled release
release dosage
form containing
containing gnrh
Prior art date
Application number
EEP200100293A
Other languages
English (en)
Estonian (et)
Inventor
Qi Steve
Akinsanya Karen
Hayward Amanda
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of EE200100293A publication Critical patent/EE200100293A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EEP200100293A 1998-12-03 1999-12-02 Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II EE200100293A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
PCT/GB1999/004045 WO2000032218A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Publications (1)

Publication Number Publication Date
EE200100293A true EE200100293A (et) 2002-08-15

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100293A EE200100293A (et) 1998-12-03 1999-12-02 Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II

Country Status (22)

Country Link
EP (1) EP1140133A1 (tr)
JP (1) JP2002531411A (tr)
KR (1) KR20010089538A (tr)
CN (1) CN1332635A (tr)
AU (1) AU770676B2 (tr)
BR (1) BR9915943A (tr)
CA (1) CA2353798A1 (tr)
CZ (1) CZ20011893A3 (tr)
EE (1) EE200100293A (tr)
GB (1) GB2344287A (tr)
HR (1) HRP20010421A2 (tr)
HU (1) HUP0104943A3 (tr)
IL (1) IL143496A0 (tr)
MX (1) MXPA01005543A (tr)
NO (1) NO20012636L (tr)
NZ (1) NZ511984A (tr)
PL (1) PL348575A1 (tr)
RU (1) RU2233170C2 (tr)
SK (1) SK7552001A3 (tr)
TR (1) TR200102273T2 (tr)
WO (1) WO2000032218A1 (tr)
ZA (1) ZA200104530B (tr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614532A1 (en) * 2005-07-26 2007-02-01 Georg-August-Universitaet Goettingen Method for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
MX2013006304A (es) 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
MX356000B (es) 2012-06-21 2018-05-08 Hoffmann La Roche Analogos de glucagon que exhiben actividad del receptor gip.
CN104981251B (zh) 2012-09-26 2018-03-20 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
EP2970511B1 (en) 2013-03-14 2020-09-30 Indiana University Research and Technology Corporation Insulin-incretin conjugates
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
CN104789524A (zh) * 2015-04-30 2015-07-22 四川大学 骨质疏松大鼠原代成骨细胞分离培养方法及应用
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2020505379A (ja) * 2017-01-20 2020-02-20 イミューン システム レギュレェイション ホールディング エービー 新規化合物（イムノレリン）
MA49508A (fr) 2017-06-30 2020-05-06 Amgen Inc Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
MA56289B1 (fr) 2017-08-03 2022-04-29 Amgen Inc Mutéines d'interleukine-21 et méthodes de traitement
EP4141005B1 (en) 2017-09-08 2024-04-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN118667021A (zh) 2017-09-18 2024-09-20 加利福尼亚大学董事会 紧密连接蛋白6抗体和治疗癌症的方法
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CA3134056A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
JP7066913B2 (ja) * 2019-03-26 2022-05-13 ノベルファーマ株式会社 持続型脂肪酸結合ＧｎＲＨ誘導体及びこれを含む薬剤学的組成物
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
JP2022538829A (ja) 2019-06-24 2022-09-06 アムジェン インコーポレイテッド 癌治療のためのＳＩＲＰγの阻害
WO2021042048A1 (en) 2019-08-30 2021-03-04 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
DE3414595A1 (de) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
DE3634435A1 (de) * 1986-10-09 1988-04-14 Hoechst Ag Analoga von gonadoliberin mit verbesserter loeslichkeit, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
WO1997047743A1 (en) * 1996-06-13 1997-12-18 Zymogenetics, Inc. Human type ii gonadotropin-releasing hormone receptor
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
GB2343182A (en) * 1998-10-27 2000-05-03 Ferring Bv Use of GnRH-II and analogues thereof for the treatment of osteoporosis

Also Published As

Publication number Publication date
RU2233170C2 (ru) 2004-07-27
TR200102273T2 (tr) 2001-12-21
PL348575A1 (en) 2002-06-03
JP2002531411A (ja) 2002-09-24
BR9915943A (pt) 2001-08-21
CZ20011893A3 (cs) 2002-05-15
MXPA01005543A (es) 2003-07-14
GB9826662D0 (en) 1999-01-27
HUP0104943A3 (en) 2002-08-28
IL143496A0 (en) 2002-04-21
HUP0104943A2 (en) 2002-06-29
NO20012636L (no) 2001-07-12
GB2344287A (en) 2000-06-07
AU1573200A (en) 2000-06-19
NO20012636D0 (no) 2001-05-29
NZ511984A (en) 2002-11-26
SK7552001A3 (en) 2002-02-05
HRP20010421A2 (en) 2002-06-30
ZA200104530B (en) 2002-06-04
EP1140133A1 (en) 2001-10-10
KR20010089538A (ko) 2001-10-06
AU770676B2 (en) 2004-02-26
CN1332635A (zh) 2002-01-23
WO2000032218A1 (en) 2000-06-08
CA2353798A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
EE200100293A (et) Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II
TR200003788A3 (tr) Yavas salimli oral dozaj bilesim.
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
ZA99454B (en) Novel dosage form.
DE69834019D1 (de) Dose
DK1600154T3 (da) Osmotisk doseringsform med forlænget frigivelse
ATE298748T1 (de) (1,4')-bipiperidin verbindungen
MX238612B (es) Compuestos que contienen superabsorbente.
TR199901077A3 (tr) Ispençiyari formülasyonlar.
DE69928777D1 (de) Dosierspender
NO20005913L (no) Legemiddelsammensetning
ZA200108000B (en) Cosmetic compounds.
EE03903B1 (et) Omeprasooli ravimvorm
ZA200007715B (en) Stable extended release oral dosage composition.
NO992692L (no) Nefadozon doseringsform
DE59900501D1 (de) Feste, schnellzerfallende cetirizin-formulierungen
IT1321100B1 (it) Dispositivo di asservimento per freno.
IT1309578B1 (it) Composizione fotoinduribile pigmentata.
BR0014932B1 (pt) conjunto de retenção.
MXPA03001425A (es) Compuestos farmaceuticos.
ID22228A (id) Turunan-turunan 16-hidroksi-11-(disubstitusifenil)-estra-4,9-diena
DE50015811D1 (de) Retardersystem
EE200000022A (et) Uus ravimvorm
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
IT1304443B1 (it) Dispositivo formatore di gruppi di sigarette.